

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center











